Clinical trials located in

Krakow

Krakow city is located in Poland. Currently, 11 clinical trials are being conducted in this city.

Krakow, Poland’s former royal capital, is steeped in rich history and cultural heritage. Founded in the 7th century, it boasts the Wawel Castle, a symbol of national identity. The city’s Main Market Square, one of Europe’s largest medieval squares, is home to the Cloth Hall and St. Mary’s Basilica. Krakow’s Jewish Quarter, Kazimierz, is renowned for its historical significance and vibrant culture. The city also serves as a gateway to the Auschwitz-Birkenau Memorial and Museum, a poignant reminder of WWII atrocities.

  • CT-EU-00117573

    Study of Combination Therapy for Melanoma After Anti-PD-1 Treatment

    This clinical trial is comparing two different treatment approaches for advanced melanoma, which is a type of skin cancer that has spread to other parts of the body. If you have a specific gene mutation called BRAF and have previously received treatment with certain immunotherapy drugs like nivolumab or pembrolizumab, you may be eligible for this study.

    One treatment approach involves receiving three study medicines: pembrolizumab given through an IV every 3 weeks, along with encorafenib and binimetinib taken by mouth daily at home. The other approach involves receiving two study medicines: ipilimumab and nivolumab given through an IV every 3 weeks for the first 4 doses, followed by nivolumab alone every 4 weeks. Both treatment approaches will be given for around 2 years, but there is no time limit for the encorafenib and binimetinib treatment.

    The study team will closely monitor your condition during regular visits to the clinic to see how you are responding to the treatment. The main goal is to determine which treatment approach is more effective in shrinking or eliminating the melanoma tumors. Around 150 participants will be enrolled in this study and randomly assigned to one of the two treatment groups.

    CzechiaGermanyItalyPolandSlovakiaSpainUnited Kingdom
  • Study of an experimental drug TL-895 for myelofibrosis or indolent systemic mastocytosis

    This here clinical trial is studying a new experimental drug called TL-895. TL-895 is taken by mouth and works by blocking certain proteins called tyrosine kinases that are involved in causing myelofibrosis and indolent systemic mastocytosis.

    Participants in the study will receive TL-895 orally in varying doses based on their specific group assignment. These doses range from 150 mg to 450 mg, and the administration could be either once or twice daily, continuing in a consistent 28-day cycle. The primary goal of the study is to determine the recommended phase 2 dose (RP2D) for TL-895 in each patient group based on safety and tolerability data. Additionally, the study aims to assess the effectiveness of TL-895 in reducing spleen volume and improving symptoms associated with Myelofibrosis over a 24-week period.

    BelgiumGermanyPolandSpain
  • Study on Secukinumab for Rotator Cuff Tendinopathy

    This here clinical trial is aimin’ to see if a new medicine called secukinumab can help folks with moderate to severe rotator cuff tendinopathy, which is a painful condition affectin’ the shoulder. The study will compare secukinumab to a placebo, which is like a fake medicine with no active ingredients.

    Now, if you join this trial, you’ll be given either secukinumab or the placebo by injection under the skin every week for the first month, and then once a month after that for another couple of months. The doctors will be keepin’ a close eye on your shoulder symptoms like pain, weakness, stiffness, and any mechanical issues you might be havin’.

    The main thing they’ll be lookin’ at is how much your physical shoulder symptoms improve after 16 weeks of treatment with secukinumab compared to the placebo. They’ll be usin’ a special questionnaire called the Western Ontario Rotator Cuff Index to measure them symptoms.

    Now, durin’ the trial, you’ll need to keep takin’ any anti-inflammatory medicines you’re already on, and keep up with your physical therapy exercises too. But you won’t be allowed to get no steroid injections or increase your medicine doses without the doctors’ say-so.

    After the 16 weeks of treatment, there’ll be another 8 weeks where the doctors will check if the effects of the medicine are lastin’. So in total, you’d be in the study for around 6 months if you join up.

    DenmarkGreeceHungaryItalyPolandSpain
  • Study on combining two drugs – Fianlimab and Cemiplimab in patients with previously untreated melanoma

    This study examines two drugs, fianlimab and cemiplimab, given together for the treatment of melanoma. The main goal is to see how effective this drug combination is in treating melanoma compared with pembrolizumab, which is already approved for the treatment of melanoma in adults. The study will also look at whether there are any differences in the effects of these experimental drugs in adolescents and adults.

    Scientists also want to learn about other key issues: what side effects may occur from taking these experimental drugs, how much of the drugs enter the bloodstream over time, and whether the body produces antibodies to the drugs that could make them less effective or cause side effects. They will also check whether taking medications improves patients’ quality of life. Fianlimab and cemiplimab will be administered by intravenous infusion, and pembrolizumab will be administered by intravenous infusion.

    AustriaBelgiumCzechiaFranceGermanyHungaryItalyNetherlandsPolandRomaniaSpainUnited Kingdom
  • Study of KRT-232 Combined with Ruxolitinib for Myelofibrosis Patients

    This here clinical trial is looking at a new drug called KRT-232 that’s taken by mouth. The study aims to see if combining KRT-232 with the existing drug ruxolitinib can help folks with myelofibrosis who ain’t responding well enough to just taking ruxolitinib alone.

    The main goal in the first part of the study is to find the right dose of KRT-232 to use when combined with ruxolitinib. They’ll be looking closely at any side effects to make sure the dose is safe. In the second part, they’ll check if the combination of the two drugs can shrink the size of the spleen by at least 35% after 6 months of treatment.

    BulgariaFranceGermanyItalyPolandSpain
  • Study of the effectiveness of CPL409116 in the treatment of rheumatoid arthritis

    A clinical trial is being presented that focuses on evaluating the efficacy and safety of a new drug called CPL409116 in individuals with active rheumatoid arthritis (RA) who have not achieved improvement with methotrexate alone. The study is designed to last for 12 weeks and aims to enroll approximately 100 participants, who will be divided into four groups. Each group will receive different doses of CPL409116 or a placebo, in addition to their continued methotrexate treatment.

    CPL409116 is a promising drug that works by targeting specific pathways in the body known to contribute to inflammation and RA symptoms. By inhibiting these pathways, CPL409116 could potentially reduce disease activity and improve symptoms. The main objective of this study is to determine how well CPL409116 can decrease disease activity compared to a placebo, which will be measured using the DAS28(CRP) score. This score takes into account the number of swollen or tender joints, the level of a specific protein in the blood that indicates inflammation, and how the patient assesses their disease activity.

    Participants in this study will be randomly assigned to one of the treatment groups and will take the study drug or placebo twice daily for 85 consecutive days. It is important for participants to have been on a stable dose of methotrexate for at least 12 weeks prior to joining the study, with no dosage changes for at least 8 weeks before the study begins.

    This study aims not only to evaluate the efficacy of CPL409116 but also its safety, ensuring that it is well-tolerated by participants. If someone is struggling with active rheumatoid arthritis and has not achieved an adequate response to methotrexate, this study may provide an opportunity to access a potentially new treatment option while contributing to significant research that could benefit other individuals with RA in the future.

    Poland
  • Comparison of zibotentan/dapagliflozin with dapagliflozin alone in the treatment of chronic kidney disease with high proteinuria

    The study aims to understand how to better treat people with chronic kidney disease (CKD) and high proteinuria. This study is in its third phase and involves multiple centers where participants will be closely monitored. The main goal is to compare the effectiveness, safety, and how well participants tolerate a combination treatment of zibotentan/dapagliflozin versus dapagliflozin alone.

    During this study, participants will be randomly assigned to one of two groups. One group will receive the combination of zibotentan and dapagliflozin, while the other group will receive only dapagliflozin. Both treatments aim to slow down the decline in kidney function, which is a major concern for people with CKD and high proteinuria. The key measure of success for this study is the change in eGFR from baseline, which is a test used to check how well the kidneys are working, specifically by measuring the estimated glomerular filtration rate (eGFR). This will be assessed at the 24-month mark of the study.

    This research is crucial because it could lead to better treatment options for those suffering from CKD and high proteinuria, potentially improving their quality of life and health outcomes.

    AustriaBulgariaDenmarkFranceGermanyItalyNetherlandsNorwayPolandSlovakiaSpainSwedenUnited Kingdom
  • ARTEMIS study: Protecting kidney health in heart surgery patients with Ravulizumab

    The ARTEMIS study aims to find a new way to protect people with chronic kidney disease (CKD) undergoing heart surgery requiring the use of a heart-lung machine, also known as cardiopulmonary bypass (CPB). The main aim of this study is to see if a single dose of a drug called ravulizumab given intravenously can reduce the risk of serious kidney problems after surgery, compared with a placebo. Kidney issues are grouped under serious adverse events, and investigators will monitor them for up to 90 days after surgery. The study is carefully controlled and participants will not know whether they are receiving ravulizumab or a placebo to ensure the results are unbiased. This is an important test for people with chronic kidney disease undergoing heart surgery because it may lead to better outcomes and a lower risk of kidney damage after surgery.

    GermanyItalyNetherlandsPolandSpainUnited Kingdom
  • A study of relacorilant in the treatment of hypercortisolism (Cushing’s syndrome) in patients with adrenal adenoma

    This clinical trial focuses on testing the effectiveness and safety of a drug called relacorilant in the treatment of patients with hypercortisolism (Cushing’s syndrome). Hypercortisolism is a condition in which there is too much cortisol in the body, which may occur due to an adenoma or hyperplasia of the adrenal glands that secrete cortisol. This condition can lead to diabetes or impaired glucose tolerance and/or uncontrolled high blood pressure.

    The study is in phase III, which means that the effectiveness and safety of the drug are compared with placebo. This is a double-blind, placebo-controlled study, which means neither participants nor researchers know who is receiving the actual drug and who is receiving the placebo to ensure unbiased results.

    Participants in this study will be randomly assigned to receive relacorilant or placebo for 22 weeks. The main goals of the study are to see how well relakorilant can improve blood sugar levels in patients with diabetes or impaired glucose tolerance, and how it affects blood pressure in people with high blood pressure. Additionally, the study will monitor the safety of relacorilant by recording any adverse events that occur.

    People who complete the study may have the opportunity to continue with a follow-up study, which may provide further information on the long-term effects and benefits of relacorilant.

    AustriaBulgariaGermanyItalyPolandRomaniaSpain
  • Sparsentan Treatment Study for Children with Kidney Diseases

    We are excited to introduce a clinical trial focused on the study of Sparsentan treatment in children and adolescents with certain types of kidney diseases that lead to protein loss in urine, known as proteinuric glomerular diseases. This includes conditions like Focal Segmental Glomerulosclerosis (FSGS), Minimal Change Disease (MCD), Immunoglobulin A Nephropathy (IgAN), IgA Vasculitis (IgAV), and Alport Syndrome (AS).

    The main goal of this study is to understand how safe, effective, and tolerable Sparsentan is when given as an oral suspension or tablet. We are particularly interested in seeing how this treatment can change the levels of protein in the urine over a period of 108 weeks.

    This study is designed as a Phase 2, Open-Label, Single-Arm trial, meaning all participants will receive the treatment, and there will not be a comparison group receiving a placebo. We are looking to enroll approximately 67 pediatric subjects, aged 1 year to less than 18 years, who have been diagnosed with one of the specified conditions. The study is divided into three populations based on the specific disease and age groups, with different dosages of Sparsentan being tested across these groups.

    The safety of the participants will be closely monitored throughout the study, with a special focus on any treatment-emergent adverse events, serious adverse events, and any adverse events that may lead to discontinuation of the treatment. Additionally, we will measure the change in the urine protein/creatinine ratio (UP/C) from the start of the study to week 108 to assess the effectiveness of Sparsentan in reducing proteinuria.

    This study represents an important step towards finding a potentially effective treatment for children and adolescents suffering from these challenging kidney diseases. If you or your child are dealing with one of these conditions and are interested in participating, we encourage you to consider this unique opportunity.

    GermanyItalyNetherlandsPolandSpainSwedenUnited Kingdom

See more clinical trials in other cities in Poland:

.